Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardio Diagnostics Holdings (CDIO) Change in Accured Expenses (2022 - 2025)

Cardio Diagnostics Holdings' Change in Accured Expenses history spans 4 years, with the latest figure at $102010.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 348.85% year-over-year to $102010.0; the TTM value through Sep 2025 reached $75926.0, up 113.85%, while the annual FY2024 figure was -$155552.0, 80.1% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $102010.0 at Cardio Diagnostics Holdings, up from -$59457.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $482589.0 in Q2 2022 and bottomed at -$379862.0 in Q4 2023.
  • The 4-year median for Change in Accured Expenses is -$28340.0 (2023), against an average of -$49175.1.
  • The largest annual shift saw Change in Accured Expenses crashed 1430.18% in 2023 before it surged 348.85% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at -$94956.0 in 2022, then plummeted by 300.04% to -$379862.0 in 2023, then surged by 103.38% to $12853.0 in 2024, then skyrocketed by 693.67% to $102010.0 in 2025.
  • Per Business Quant, the three most recent readings for CDIO's Change in Accured Expenses are $102010.0 (Q3 2025), -$59457.0 (Q2 2025), and $20520.0 (Q1 2025).